Severe COVID‐19 is associated with endothelial activation and abnormal glycosylation of von Willebrand factor in patients undergoing hemodialysis

Mobayen, Golzar; Dhutia, Amrita; Clarke, Candice; Prendecki, Maria; McAdoo, Stephen; Keniyopoullos, Renos; Malik, Talat; Laffan, Michael; Willicombe, Michelle; McKinnon, Thomas

BACKGROUND: A major clinical feature of severe coronavirus diease 2019 (COVID‐19) is microvascular thrombosis linked to endothelial cell activation. Consistent with this, a number of studies have shown that patients with severe COVID‐19 have highly elevated plasma levels of von Willebrand Factor (VWF) that may contribute to the prothrombotic phenotype. In the current study, we investigated the extent of endothelial activation in patients receiving hemodialysis who had either mild or severe COVID‐19. METHODS: Plasma VWF, ADAMTS‐13, angiopoietin‐2 (Ang2), and syndecan‐1 levels were determined by ELISA. The sialic acid content of VWF was investigated using a modified ELISA to measure elderberry bark lectin, specific for sialic acid residues, binding to VWF. RESULTS: Patients receiving hemodialysis with severe COVID‐19 had significantly higher plasma levels of VWF and lower ADAMTS‐13. VWF levels peaked and were sustained during the first 10 days after positive confirmation of infection. While Ang2 trended toward being higher in severely ill patients, this did not reach significance; however, severely ill patients had significantly higher soluble syndecan‐1 levels, with high levels related to risk of death. Finally, higher VWF levels in severely ill patients were correlated with lower VWF sialic acid content. CONCLUSIONS: Severe COVID‐19 in patients undergoing hemodialysis is associated with both acute and sustained activation of the endothelium, leading to alteration of the VWF/ADAMTS‐13 axis. Lower VWF sialic acid content represents altered VWF processing and further confirms the disturbance caused to the endothelium in COVID‐19.